Snail基因修饰对骨髓间充质干细胞CXCR4表达水平及向SDF-1趋化能力的影响

为研究Snail基因修饰对骨髓间充质干细胞(MSCs)CXCR4表达水平及向SDF-1趋化能力影响, 将重组真核表达载体(pCAGGSneo-snail-HA)及对照空质粒(pCAGGSneo)转染MSCs, 采用免疫荧光细胞化学染色、荧光标记流式细胞仪技术及RT-PCR检测细胞CXCR4表达水平; 体外跨膜趋化实验评价MSCs向SDF-1趋化能力, 观察抗CXCR4中和抗体的干预作用。MSCs-Sna的CXCR4表达水平明显高于MSCs-neo。MSCs-Sna在SDF-1诱导下细胞迁移量较MSCs-neo显著增加(P<0.05)。抗CXCR4中和抗体可显著减少SDF-1a诱导的MSCs-Sna趋化运动。研究提示通过上调Snail表达而提高MSCs向正调节表达SDF-1的受损组织迁移效率的可行性, 为优化MSCs迁移力的研究提供了实验基础。     

贴壁法分离培养大鼠骨髓间充质干细胞的生物学特性

目的建立一种简便有效的体外分离纯化及培养扩增大鼠骨髓间充质干细胞(MSCs)的方法。研究MSCs的生物学特性,为血管组织工程提供理想的种子细胞。方法贴壁培养法分离纯化大鼠MSCs体外培养和连续传代,在倒置显微镜下连续观察细胞的形态变化;利用MTT法测定MSCs的生长曲线;行免疫组化方法鉴定MSCs膜抗原;分别加成骨、成脂肪诱导剂后MSCs体外培养1到3周,分别做碱性磷酸酶(ALP)、VonKossa染色及油红O染色,观察细胞形态变化、成骨及成脂肪分化结果。结果MSCs体外培养生长状况良好,呈均一的成纤维细胞样,表达波形蛋白(Vimentin)、α-平滑肌肌动蛋白(α-SMA),不表达层粘连蛋白(Laminin)、CD34、VIII因子相关抗原(VIII)。经体外诱导后具有多向分化潜能。结论贴壁培养法能有效分离纯化大鼠MSCs,用此方法培养的细胞生长稳定,增殖能力活跃,具有MSCs的一般生物学特性,为其成为血管组织工程理想的种子细胞提供了进一步的支持。     

Runx2基因对骨髓间充质干细胞体外迁移能力的影响

目的:观察Runt相关转录因子2(Runx2)基因过表达对骨髓间充质干细胞(MSCs)体外迁移能力的影响。方法:分离培养兔MSCs,用已构建的携带Runx2基因的腺病毒载体Ad-Runx2、单纯腺病毒及AMD3100处理MSCs;应用Transwell小室检测MSCs体外迁移能力的变化,QPCR检测基质细胞衍生因子(SDF-1)和趋化因子受体(CXCR4)m RNA的表达,ELISA检测各组细胞培养液上清中SDF-1的含量,Western印迹检测CXCR4蛋白表达水平。结果:Ad-Runx2转染MSCs组细胞迁移数明显增多(P0.01),AMD3100处理MSCs后细胞迁移数明显降低(P0.01);QPCR、ELISA、Western印迹结果显示Ad-Runx2转染能促进MSCs中SDF-1及CXCR4的表达(P0.01)。结论:Runx2基因过表达能促进MSCs的体外迁移,这与其激活SDF-1/CXCR4信号轴相关。     

CXCR4基因转染人脐带间充质干细胞移植治疗糖尿病肾病的实验研究

摘要 目的：探讨过表达CXCR4的人脐带间充质干细胞（human umbilical cord mesenchymal stem cell, hUC-MSCs）移植后对糖尿病肾病的治疗作用。方法：构建CXCR4的慢病毒表达载体，并建立过表达 CXCR4 的人脐带间充质干细胞（CXCR4-MSCs）。采用8周龄健康雌性SD大鼠75只，其中15只为正常对照组，60只为实验组。实验组糖尿病成模后一个月，将糖尿病实验大鼠60只随机分为4组：①移植CXCR4-MSCs组(CXCR4基因转染MSCs组)，即CXCR4组；②移植null-MSCs组(空质粒未转染CXCR4基因的MSCs组)，即null-MSCs；③移植MSCs组( MSCs组)；④PBS组(未移植任何的MSCs，单纯PBS注射，PBS组)。将CXCR4-MSCs、null-MSCs及MSCs消化离心，取含1×106个细胞悬液经尾静脉分别注入CXCR4-MSCs组、null-MSCs组及MSCs组大鼠体内，PBS组注射l mL PBS。干细胞治疗8周后，处死五组大鼠。各组大鼠处死前放代谢笼留取24 h尿，计算尿量，保存送检。处死前尾静脉采血检测血糖、称体重并记录。观察血糖、肾脏肥大指数、肾重、体重、24小时尿蛋白排泄量，并观察肾脏组织病理学改变。结果：60只SD雌性大鼠糖尿病模型成功率达100％，至实验8周糖尿病大鼠总共死亡14只，存活率达76.67％。实验开始后的8周，所有CXCR4组、Null-MSCs组、MSCs组、PBS组大鼠与正常组比较，体重均明显减轻(P<0.01)，血糖明显升高(P<0.01)。MSCs治疗后8周，除正常组外，其余各组大鼠血糖、肾重、肾重/体重比、24小时尿蛋白均显著增高，体重显著降低(P<0.05)；与PBS组相比，CXCR4组、null-MSCs组，MSCs组大鼠的肾重、肾重/体重比、24小时尿蛋白均明显降低(P<0.05)，体重无明显增加，血糖无明显降低(P>0.05)。CXCR4组大鼠的肾重、肾重/体重比、24小时尿蛋白较除正常组外的各组均明显降低(P<0.05)。糖尿病成模后，给予大鼠尾静脉注射干细胞悬液或等量培养液，注射后8周，除正常组外，其余各组PAS染色可见大鼠肾小球肥大，肾小球基底膜增厚、系膜增生、系膜基质增多，部分肾小球出现明显硬化，符合糖尿病肾病中期病理表现。CXCR4组大鼠肾小球系膜基质增生较其余各组大鼠减少(P<0.05)。结论：转染CXCR4的MSCs可改善糖尿病肾病。     

基质衍生因子(SDF-1)对骨髓间充质干细胞定向迁移的影响

目的:研究基质细胞衍生因子-1(SDF-1)/CXCR4轴在骨髓间充质干细胞迁徙到受损胰腺中的作用。方法:密度梯度离心、贴壁培养骨髓间充质干细胞,建立STZ诱导糖尿病模型并制备正常和受损胰腺组织提取液,利用Transwell小室体外迁移体系观察不同浓度SDF-1和不同组织提取液对骨髓间充质干细胞的趋化作用,及SDF-1/CXCR4特异抑制剂AMD3100对骨髓间充质干细胞迁移的影响。结果:成功培养了骨髓间充质干细胞并建立了糖尿病大鼠模型。SDF-l对骨髓间充质干细胞有剂量依赖性的趋化作用,造模1周的胰腺组织提取液对骨髓间充质干细胞有明显的趋化作用,而这种作用可部分被SDF-1受体CXCR4的抑制剂AMD3100抑制。结论:受损胰腺组织提取液对骨髓间充质干细胞有明显的趋化作用,SDF-1/CXCR4轴可能在组织提取液趋化骨髓间充质干细胞迁移中起主要的作用。     

坏死细胞释放IL-1β对血管平滑肌细胞侵袭和迁移的影响及机制研究

目的研究坏死血管平滑肌细胞释放IL-1β对周围正常细胞侵袭和迁移的影响,并探讨其可能的机制。方法无血清低糖低氧条件下培养细胞,建立细胞坏死模型,收集坏死细胞培养上清液,用于干预正常血管平滑肌细胞。实验设坏死上清组（NCS）、IL-1β组、NCS＋IL-1RA组和对照组（Control）。Tran-swell小室实验和细胞划痕实验检测各组细胞侵袭和迁徙能力,RT-PCR和Western印迹检测各组MMP-2和MMP-9的表达,Western印迹检测各组NF-κB的激活情况。结果NCS组和IL-1β组细胞侵袭和迁移能力均显著高于对照组（P〈0．05）,NCS＋IL-1RA组细胞侵袭和迁移能力显著低于NCS组和IL-1组（P〈0．05）;对照组和NCS＋IL．1RA组NF-κB、MMP-2和MMP-9均显著低于NCS组和IL-1β组（P〈0．05）,IκB显著高于NCS组和IL-1β组（P〈0．05）。使用NF-κB特异性抑制剂处理后,NCS组和IL-1β组细胞侵袭和迁移能力显著性降低（P〈0．01）;MMP-2和MMP-9的表达也显著性减少（P〈0．01）。结论坏死血管平滑肌细胞能够上调MMP-2和MMP-9的表达,促进正常细胞的侵袭和迁移,且这种促进作用与IL-1β的大量释放诱导NF-κB的活化有关。     

siRNA联合沉默MMP-9和FAK基因对小鼠黑色素瘤高转移细胞B16F10体外侵袭和迁移的影响

目的： 观察双基因联合干扰MMP-9和FAK对小鼠黑色素瘤高转移细胞B16F10体外侵袭、迁移能力的影响。方法：分别构建pGV102-MMP9-siRNA,pGV102-FAK-siRNA重组质粒载体,脂质体^TM2000介导转染小鼠黑色素瘤B16F10细胞,实验分为空白对照组、Anti-MMP-9组,Anti-FAK组、Anti-MMP-9 &FAK组、阴性对照组。经G418筛选GFP+克隆,流式细胞仪分析阳性率,激光共聚焦观察转染后细胞形态,半定量RT-PCR检测各组B16F10细胞MMP-9和FAK基因的mRNA转录水平,Transwell侵袭、迁移实验测定各组B16F10细胞体外侵袭、迁移能力。结果： 经G418筛选,3个转染组阳性率分别为92.41±1.64%,95.72±0.21%,91.52±0.11%,且转染后细胞形态良好;与空白对照组相比,3个转染组的MMP-9,FAK mRNA转录水平下降明显（P<0.01）,迁移、侵袭能力明显降低（P<0.01）,但Anti-MMP-9 &FAK组细胞侵袭迁移能力显著低于Anti-MMP-9 组和Anti-FAK组（P<0.01）。结论： 相比单独沉默MMP-9 或FAK,联合沉默MMP-9 和FAK可明显降低小鼠黑色素瘤B16F10细胞体外迁移、侵袭能力。     

大鼠骨髓间充质干细胞的分离纯化与初步鉴定

目的：探讨体外分离、纯化大鼠骨髓间充质干细胞(mesenchymal stem cells,MSCs)的方法,分析其部分表型特点。方法：用密度梯度离心结合贴壁培养法分离纯化大鼠骨髓MSCs,传代扩增,测定生长曲线,形态学观察,免疫细胞化学及图像分析测定细胞表面抗原和细胞外基质蛋白表达情况。结果：MSCs属骨髓中单个核细胞,密度梯度离心结合贴壁培养法能有效分离纯化大鼠骨髓MSCs,MSCs在含10％小牛血清的L-DMEM中生长性状相对稳定,1、3、5代细胞生长曲线基本一致,增殖速度快。细胞呈均一的成纤维细胞样,均一表达CD44、CD54、纤维粘连蛋白(Fibronectin,FN)、Ⅰ型胶原(CollagenⅠ)。结论：本实验建立了一种体外分离纯化、培养扩增大鼠骨髓MSCs的方法,MSCs稳定表达CD44、CD54、FN、CollagenⅠ。     

骨髓间充质干细胞源神经细胞移植治疗帕金森病大鼠模型

目的探讨骨髓间充质干细胞（mesenchymal stemcells,MSCs）源神经细胞脑内移植对帕金森病（Parkinson s disease,PD）大鼠的治疗作用。方法贴壁培养法分离、培养大鼠骨髓MSCs,脑匀浆上清诱导第3代MSCs向神经细胞分化,采用免疫细胞化学法鉴定诱导分化后细胞的性质,激光共聚焦显微镜检测诱导前后细胞Ca2＋浓度变化,6只PD大鼠行纹状体内MSCs源神经细胞移植作为细胞移植组,6只PD大鼠作为对照组。细胞移植术后4周检测PD大鼠的行为变化,观察移植细胞在脑内的分布情况。结果倒置显微镜下可见MSCs呈纺锤形和多角形,有1～2个核仁,MSCs经脑匀浆上清诱导后其胞体折光性增强,发出数个细长突起,互相交织成网,有的似轴突。诱导后细胞表达神经元特异性标志物神经元特异性烯醇化酶（NSE）和神经丝蛋白（NF）,胞质Ca2＋荧光强度显著增强,可推测诱导后的细胞为MSCs源神经细胞,将BrdU标记的MSCs源神经细胞移植到PD大鼠纹状体治疗4周后,可见细胞散在分布于注射侧脑组织,有少量细胞可迁移到对侧脑组织,PD大鼠的旋转行为得到显著改善。结论MSCs源神经细胞移植治疗帕金森病大鼠可使其旋转行为得到改善。     

一种提高体外培养细胞中期分裂相的新方法

为了提高体外培养细胞中期分裂相,用黄牛胎儿成纤维细胞系 （YFF）和西门塔尔小牛成纤维细胞系（CNF）为实验材料,先经4℃低温休克再用秋水仙素处理后制备染色体,比较了不同低温休克处理时间获得的中期分裂相百分率,并运用该方法对20代内YFF和CNF核型变异进行了分析。实验发现,YFF和 CNF经低温休克中期分裂相百分率显著高于对照组（P<0.05）。其中, 20 h低温组中期分裂相（31.7﹪和40.2﹪）高于对照组（4.7﹪和6.4﹪）5倍以上（P<0.01）。实验结果表明,4℃低温休克法是一种提高体外培养细胞中期分裂相的简便方法,适于监测体外培养细胞核型变异。     

HIV glycoprotein gp120 enhances mesenchymal stem cell migration by upregulating CXCR4 expression

Background

HIV infection and/or the direct pathogenic effects of circulating HIV proteins impairs the physiological function of mesenchymal stem cells (MSCs), and contribute to the pathogenesis of age-related clinical comorbidities in people living with HIV. The SDF-1/CXCR4 pathway is vital for modulating MSC proliferation, migration and differentiation. HIV glycoprotein gp120 inhibits SDF-1 induced chemotaxis by downregulating the expression and function of CXCR4 in monocytes, B and T cells. The influence of gp120 on CXCR4 expression and migration in MSCs is unknown.

Serum‐free spheroid suspension culture maintains mesenchymal stem cell proliferation and differentiation potential

There have been many clinical trials recently using ex vivo‐expanded human mesenchymal stem cells (MSCs) to treat several disease states such as graft‐versus‐host disease, acute myocardial infarction, Crohn's disease, and multiple sclerosis. The use of MSCs for therapy is expected to become more prevalent as clinical progress is demonstrated. However, the conventional 2‐dimensional (2D) culture of MSCs is laborious and limited in scale potential. The large dosage requirement for many of the MSC‐based indications further exacerbates this manufacturing challenge. In contrast, expanding MSCs as spheroids does not require a cell attachment surface and is amenable to large‐scale suspension cell culture techniques, such as stirred‐tank bioreactors. In the present study, we developed and optimized serum‐free media for culturing MSC spheroids. We used Design of Experiment (DoE)‐based strategies to systematically evaluate media mixtures and a panel of different components for effects on cell proliferation. The optimization yielded two prototype serum‐free media that enabled MSCs to form aggregates and proliferate in both static and dynamic cultures. MSCs from spheroid cultures exhibited the expected immunophenotype (CD73, CD90, and CD105) and demonstrated similar or enhanced differentiation potential toward all three lineages (osteogenic, chondrogenic, adipogenic) as compared with serum‐containing adherent MSC cultures. Our results suggest that serum‐free media for MSC spheroids may pave the way for scale‐up production of MSCs in clinically relevant manufacturing platforms such as stirred tank bioreactors. © 2014 American Institute of Chemical Engineers Biotechnol. Prog., 30:974–983, 2014     

Protective Effects of Mesenchymal Stem Cells with CXCR4 Up-Regulation in a Rat Renal Transplantation Model

The homing of mesenchymal stem cells to injured tissue, which is important for the correction of conditions such as ischemia-reperfusion injury (IRI) and immunolesions, has been performed previously, but with poor efficiency. Substantial improvements in engraftment are required to derive clinical benefits from MSC transplantation. Chemokines are the most important factors that control cellular migration. Stromal derived factor-1 (SDF-1) is up-regulated during tissue/organ ischemia damage, and its cognate receptor, chemokine receptor 4 (CXCR4), is involved in stem cell migration. The aim of our study was to investigate CXCR4 expression in MSCs and to validate both its role in mediating migration to transplanted kidneys and its immunoregulatory effects in renal protection. Specifically, the present study was designed to investigate the short-term tissue homing of MSCs carrying genetically modified CXCR4 in a rat renal transplantation model. We tested the hypothesis that MSCs with CXCR4 over-expression can more efficiently regulate immunological reactions. Lentiviral vectors were used to over-express CXCR4 or to introduce a short hairpin ribonucleic acid (shRNA) construct targeting endogenous CXCR4 in rat MSCs. MSCs were labeled with enhanced green fluorescent protein (eGFP). After cell sorting, recipient kidneys were regionally perfused; recipient animals were injected with transduced MSCs, native MSCs, or PBS via tail vein following renal transplantation; and the effects of MSC injection were observed.     

Tanshinone IIA and astragaloside IV promote the migration of mesenchymal stem cells by up-regulation of CXCR4

Mesenchymal stem cells (MSCs) have a therapeutic potential to treat cardiovascular diseases. However, a significant barrier to MSC therapy is insufficient MSC engraftment in ischemic myocardium after systemic administration. Here, we investigated the modulatory effects of tanshinone IIA and astragaloside IV on the migration of MSCs and further defined the underlying mechanisms. CXCR4 expression in MSCs was determined by using flow cytometry, real-time PCR, and western blotting. The results showed that CXCR4 expression was significantly higher in tanshinone IIA- and astragaloside IV-stimulated MSCs than that of the control. MSC migration toward stromal cell-derived factor-1α (SDF-1α) was studied using a transwell system. MSCs treated with tanshinone IIA and astragaloside IV showed stronger migration than that of the control. Moreover, this enhanced migration ability was abrogated by a CXCR4 inhibitor. In a rat acute myocardial infarction model, MSCs stimulated with tanshinone IIA and astragaloside IV were stained with Dio and injected into model rats via the tail vein. Dio-labeled cells in myocardium sections were observed by fluorescence microscopy. Tanshinone IIA- and astragaloside IV-stimulated MSCs showed enhanced capacities to home to ischemic myocardium sites. In addition, there was no significant difference in the SDF-1α expression among groups. These data suggest that tanshinone IIA and astragaloside IV regulate MSC mobilization, at least partially via modulation of the CXCR4 expression.     

Plerixafor induces the rapid and transient release of stromal cell-derived factor-1 alpha from human mesenchymal stromal cells and influences the migration behavior of human hematopoietic progenitor cells

The interaction between the stromal cell-derived factor-1 alpha (SDF-1α, CXCL12) and its chemokine receptor CXCR4 has been reported to regulate stem cell migration, mobilization and homing. The CXCR4 antagonist plerixafor is highly efficient in mobilizing hematopoietic progenitor cells (HPCs). However, the precise regulatory mechanisms governing the CXCR4/SDF-1α axis between the bone marrow niche and HPCs remain unclear. In this study, we quantify the impact of plerixafor on the interaction between human bone marrow derived mesenchymal stromal cells (MSCs) and human CD34+ HPCs. An assessment of SDF-1α levels in the supernatant of MSC cultures revealed that exposure to plerixafor led to a transient increase but had no long-term effect. In Transwell experiments, we observed that the addition of SDF-1α significantly stimulated HPC migration; this stimulation was almost completely antagonized by the addition of plerixafor, confirming the direct impact of the CXCR4/SDF-1α interaction on the migration capacity of HPCs. We also developed a new microstructural niche model to determine the chemotactic sensitivity of HPCs. Time-lapse microscopy demonstrated that HPCs migrated actively along an SDF-1α gradient within the microchannels and the quantitative assessment of the required minimum gradient initiating this chemotaxis revealed a surprisingly high sensitivity of HPCs. These data demonstrate the fine-tuned balance of the CXCR4/SDF-1α axis and the synergistic effects of plerixafor on HPCs and MSCs, which most likely represent the key mechanisms for the consecutive mobilization of HPCs from the bone marrow niche into the circulating blood.     

Increased Migration of Human Mesenchymal Stromal Cells by Autocrine Motility Factor (AMF) Resulted in Enhanced Recruitment towards Hepatocellular Carcinoma

Background and Aims

Several reports described the migration of human mesenchymal stromal cells (MSCs) towards tumor-released factors. Autocrine motility factor (AMF) is produced by several tumors including hepatocellular carcinoma (HCC). The aim of this study was to analyze AMF involvement on MSC migration towards human HCC.

Methods

Production of AMF by HCC tumors was evaluated by western analysis. The effects of AMF on MSCs from different sources (bone marrow, adipose tissue and perivascular cells from umbilical cord) were analyzed using in vitro migration assay; metalloproteinase 2 (MMP2) activity and expression of critical genes were studied by zymography and qRT-PCR, respectively. To assess AMF involvement on the in vivo MSC migration, noninvasive fluorescence imaging was performed. To test the effect of AMF-primed MSCs on tumor development, in vitro proliferation and spheroids growth and in vivo tumor volume were evaluated.

Results

AMF produced by HCC was found to induce migration of different MSCs in vitro and to enhance their MMP2 activity. Stimulation of MSCs with recombinant AMF (rAMF) also induced the in vitro adhesion to endothelial cells in coincidence with changes in the expression levels of MMP3, AMF receptor, caveolin-1, and -2 and GDI-2. Importantly, stimulation of MSCs with rAMF increased the in vivo migration of MSCs towards experimental HCC tumors. AMF-priming of MSCs did not induce a pro-tumorigenic effect on HCC cells neither in vivo nor in vitro.

Conclusion

AMF plays a role in MSC recruitment towards HCC. However, its ability to increase MSC migration to HCC for therapeutic purposes merits further evaluation.